Abstract
Background: Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature. Hypothesis: As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Animals: 70 dogs with naturally occurring hyperadrenocorticism. Methods: Retrospective study. Each dog must have been treated for at least 6 months and should have shown a "good response" to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1-20, 20.1-30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition. Results: There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases. Conclusions and Clinical Importance: Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1078-1080 |
| Number of pages | 3 |
| Journal | Journal of Veterinary Internal Medicine |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2012 |
Fingerprint
Keywords
- Hyperadrenocorticism
- Pituitary-dependent hyperadrenocorticism
- Trilostane
ASJC Scopus subject areas
- veterinary(all)
Cite this
Trilostane Dose versus Body Weight in the Treatment of Naturally Occurring Pituitary-Dependent Hyperadrenocorticism in Dogs. / Feldman, Edward C; Kass, Philip H.
In: Journal of Veterinary Internal Medicine, Vol. 26, No. 4, 07.2012, p. 1078-1080.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Trilostane Dose versus Body Weight in the Treatment of Naturally Occurring Pituitary-Dependent Hyperadrenocorticism in Dogs
AU - Feldman, Edward C
AU - Kass, Philip H
PY - 2012/7
Y1 - 2012/7
N2 - Background: Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature. Hypothesis: As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Animals: 70 dogs with naturally occurring hyperadrenocorticism. Methods: Retrospective study. Each dog must have been treated for at least 6 months and should have shown a "good response" to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1-20, 20.1-30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition. Results: There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases. Conclusions and Clinical Importance: Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.
AB - Background: Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature. Hypothesis: As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Animals: 70 dogs with naturally occurring hyperadrenocorticism. Methods: Retrospective study. Each dog must have been treated for at least 6 months and should have shown a "good response" to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1-20, 20.1-30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition. Results: There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases. Conclusions and Clinical Importance: Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.
KW - Hyperadrenocorticism
KW - Pituitary-dependent hyperadrenocorticism
KW - Trilostane
UR - http://www.scopus.com/inward/record.url?scp=84864020602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864020602&partnerID=8YFLogxK
U2 - 10.1111/j.1939-1676.2012.00956.x
DO - 10.1111/j.1939-1676.2012.00956.x
M3 - Article
VL - 26
SP - 1078
EP - 1080
JO - Journal of Veterinary Internal Medicine
JF - Journal of Veterinary Internal Medicine
SN - 0891-6640
IS - 4
ER -